Venetoclax with hypomethylating agents might lead to eradication of measurable residual disease (MRD) persisting after intensive chemotherapy in acute myeloid leukemia (AML) patients with mutated NPM1 and rearranged CBF.

Authors :: Jiménez-Vicente C
Martínez-Roca A
Pomares H
Castaño-Diez S
Guijarro F
López-Guerra M
Bataller A
Esteban D
Cortés-Bullich A
Pérez-Valencia AI
Guardia-Torrelles A
Zugasti I
Rovira M
Fernández-Avilés F
Colomer D
Arnan M
Díaz-Beyá M
Esteve J
Source :: Leukemia research [Leuk Res] 2023 Dec; Vol. 135, pp. 107403. Date of Electronic Publication: 2023 Sep 30.
Publication Year :: 2023
Abstract: Competing Interests: Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Subjects :: Humans
Nuclear Proteins genetics
Bridged Bicyclo Compounds, Heterocyclic therapeutic use
Sulfonamides therapeutic use
Neoplasm, Residual drug therapy
Leukemia, Myeloid, Acute drug therapy
Leukemia, Myeloid, Acute genetics

Full Text Access

Tools